RRRebecca Rohrer

Rebecca Rohrer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rebecca Rohrer has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Applying prospective tree-temporal scan statistics to genomic surveillance data to detect emerging SARS-CoV-2 variants and salmonellosis clusters in New York City

    by Sharon K Greene, Julia Latash, Eric R Peterson, Alison Levin-Rector, Elizabeth Luoma, Jade C Wang, Kevin Bernard, Aaron Olsen, Lan Li, HaeNa Waechter, et al.

    Background: The detection of communicable disease clusters in genomic surveillance data typically involves the application of rule-based signaling criteria, which can be arbitrary. In contrast, scan statistics that are used for spatiotemporal cluster detection can flexibly scan in calendar time, and scan statistics that are used for pharmacovigilance can flexibly scan along hierarchical tree structures that are based on diagnosis codes. Methods: New York City (NYC) Health Department staff applied tree-temporal scan statistics prospectively to genomic surveillance data with a hierarchical nomenclature for COVID-19 and salmonellosis cases that were diagnosed among NYC residents. We searched weekly for recent case increases at any granularity, from large phylogenetic branches to small groups of indistinguishable isolates. Using free and open-source TreeScan software, we looked for emerging SARS-CoV-2 variants based on Pango lineages during August 2021–November 2023 and emerging clusters of Salmonella isolates based on allele codes during November 2022–November 2023. Results: The SARS-CoV-2 Omicron subvariant EG.5.1 first signaled as locally emerging on 22 June 2023, 7 weeks before the World Health Organization designated it as a variant of interest. During 1 year of salmonellosis analyses, TreeScan detected 15 credible clusters that were worth investigating for common exposures and two data-quality issues for correction. Conclusion: A challenge was the maintenance of timely and specific lineage assignments, and a limitation was that genetic distances between tree nodes were not considered. By automatically sifting through genomic data and generating ranked shortlists of nodes with statistically unusual recent case increases, TreeScan assisted in detecting emerging variants and clusters of communicable diseases and in prioritizing them for investigation.


  • Open Access

    Nowcasting to Monitor Real-Time Mpox Trends During the 2022 Outbreak in New York City: Evaluation Using Reportable Disease Data Stratified by Race or Ethnicity

    by Rebecca Rohrer, Allegra Wilson, Jennifer Baumgartner, Nicole Burton, Ray R Ortiz, Alan Dorsinville, Lucretia E Jones, Sharon K Greene

    Background: Applying nowcasting methods to partially accrued reportable disease data can help policymakers interpret recent epidemic trends despite data lags and quickly identify and remediate health inequities. During the 2022 mpox outbreak in New York City, we applied Nowcasting by Bayesian Smoothing (NobBS) to estimate recent cases, citywide and stratified by race or ethnicity (Black or African American, Hispanic or Latino, and White). However, in real time, it was unclear if the estimates were accurate. Objective: We evaluated the accuracy of estimated mpox case counts across a range of NobBS implementation options. Methods: We evaluated NobBS performance for New York City residents with a confirmed or probable mpox diagnosis or illness onset from July 8 through September 30, 2022, as compared with fully accrued cases. We used the exponentiated average log score (average score) to compare moving window lengths, stratifying or not by race or ethnicity, diagnosis and onset dates, and daily and weekly aggregation. Results: During the study period, 3305 New York City residents were diagnosed with mpox (median 4, IQR 3-5 days from diagnosis to diagnosis report). Of these, 812 (25%) had missing onset dates, and of these, 230 (28%) had unknown race or ethnicity. The median lag in days from onset to onset report was 10 (IQR 7-14). For daily hindcasts by diagnosis date, the average score was 0.27 for the 14-day moving window used in real time. Average scores improved (increased) with longer moving windows (maximum: 0.47 for 49-day window). Stratifying by race or ethnicity improved performance, with an overall average score of 0.38 for the 14-day moving window (maximum: 0.57 for 49 day-window). Hindcasts for White patients performed best, with average scores of 0.45 for the 14-day window and 0.75 for the 49-day window. For unstratified, daily hindcasts by onset date, the average score ranged from 0.16 for the 42-day window to 0.30 for the 14-day window. Performance was not improved by weekly aggregation. Hindcasts underestimated diagnoses in early August after the epidemic peaked, then overestimated diagnoses in late August as the epidemic waned. Estimates were most accurate during September when cases were low and stable. Conclusions: Performance was better when hindcasting by diagnosis date than by onset date, consistent with shorter lags and higher completeness for diagnoses. For daily hindcasts by diagnosis date, longer moving windows performed better, but direct comparisons are limited because longer windows could only be assessed after case counts in this outbreak had stabilized. Stratification by race or ethnicity improved performance and identified differences in epidemic trends across patient groups. Contributors to differences in performance across strata might include differences in case volume, epidemic trends, delay distributions, and interview success rates. Health departments need reliable nowcasting and rapid evaluation tools, particularly to promote health equity by ensuring accurate estimates within all strata.


  • Open Access

    Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study

    by Ghulam Rehman Mohyuddin, Jenny S. Guadamuz, Mustafa S. Ascha, Brian C.-H. Chiu, Pritesh R. Patel, Karen Sweiss, Rebecca Rohrer, Douglas Sborov, Gregory S. Calip


  • Open Access

    Applying Prospective Tree-Temporal Scan Statistics to Genomic Surveillance Data to Detect Emerging SARS-CoV-2 Variants and Salmonellosis Clusters in New York City

    by Sharon K. Greene, Julia Latash, Eric R. Peterson, Alison Levin-Rector, Elizabeth Luoma, Jade C. Wang, Kevin Bernard, Aaron Olsen, Lan Li, HaeNa Waechter, et al.

    Genomic surveillance data are used to detect communicable disease clusters, typically by applying rule-based signaling criteria, which can be arbitrary. We applied the prospective tree-temporal scan statistic (TreeScan) to genomic data with a hierarchical nomenclature to search for recent case increases at any granularity, from large phylogenetic branches to small groups of indistinguishable isolates. Using COVID-19 and salmonellosis cases diagnosed among New York City (NYC) residents and reported to the NYC Health Department, we conducted weekly analyses to detect emerging SARS-CoV-2 variants based on Pango lineages and clusters of Salmonella isolates based on allele codes. The SARS-CoV-2 Omicron subvariant EG.5.1 first signaled as locally emerging on June 22, 2023, seven weeks before the World Health Organization designated it as a variant of interest. During one year of salmonellosis analyses, TreeScan detected fifteen credible clusters worth investigating for common exposures and two data quality issues for correction. A challenge was maintaining timely and specific lineage assignments, and a limitation was that genetic distances between tree nodes were not considered. By automatically sifting through genomic data and generating ranked shortlists of nodes with statistically unusual recent case increases, TreeScan assisted in detecting emerging communicable disease clusters and in prioritizing them for investigation.


  • Open Access

    Nowcasting to Monitor Real-Time Mpox Trends During the 2022 Outbreak in New York City: An Evaluation Using Reportable Disease Data Stratified by Race or Ethnicity (Preprint)

    by Rebecca Rohrer, Allegra Wilson, Jennifer Baumgartner, Nicole Burton, Ray R Ortiz, Alan Dorsinville, Lucretia E Jones, Sharon K Greene

    BACKGROUND Applying nowcasting methods to partially accrued reportable disease data can help policymakers interpret recent epidemic trends and quickly identify and remediate health inequities. During the 2022 mpox outbreak in New York City (NYC), we applied Nowcasting by Bayesian Smoothing (NobBS) to estimate recent cases, citywide and stratified by race or ethnicity. However, in real time, it was unclear if estimates were accurate. OBJECTIVE We evaluated the accuracy of estimated mpox case counts across a range of NobBS implementation options. METHODS We evaluated NobBS performance for NYC residents with confirmed or probable mpox diagnosis or illness onset from July 8 through September 30, 2022, as compared with fully accrued cases. We used the mean absolute error (MAE), relative root mean square error (rRMSE), and 95% prediction interval (PI) coverage to compare moving window lengths, stratifying or not by race or ethnicity, diagnosis and onset time elements, and daily and weekly time units. RESULTS During the study period, 3305 NYC residents were diagnosed with mpox (median 4 days from diagnosis to diagnosis report), and 2278 patients had known illness onset (median 10 days from onset to onset report). No single moving window length performed best. As window lengths increased from 14 to 49 days, generally, MAE improved (decreased), while rRMSE worsened (increased). For the diagnosis time element, for the 14-day moving window used in real time, MAE was 9, rRMSE was 0.23, and 95% PI coverage was 96%; ranges for longer moving windows were MAE: 3–9, rRMSE: 0.25–0.30, and 95% PI coverage: 93%–100%. For the onset time element, for the 21-day moving window used in real time, MAE was 12, rRMSE was 1.07, and 95% PI coverage was 84%; ranges for other moving windows were MAE: 7–11, rRMSE: 0.75–1.42, and 95% PI coverage: 75%–99%. For any given moving window length, rRMSE worsened (increased) for stratified compared with unstratified estimates. For stratified daily diagnosis hindcasts, for the 14-day moving window used in real time, rRMSE was 0.32, and 95% PI coverage was 95%; ranges for other moving window lengths were rRMSE: 0.35–0.50 and 95% PI coverage: 96%–100%. Performance generally worsened when using onset compared with diagnosis time elements and weekly compared with daily time units. Hindcasts underestimated diagnoses in early August after the epidemic peaked, then overestimated diagnoses in late August during epidemic waning. Estimates were most accurate during September, when cases were low and stable. CONCLUSIONS For nowcasting this outbreak using NobBS, accuracy depended on the moving window length and whether cases were stratified. Health departments need additional nowcasting guidance, particularly to promote health equity by ensuring stratified estimates are accurate and to improve robustness, such as by incorporating multiple methods.

  • Open Access

    Abstract 3669: Racial/ethnic disparities in treatment with bone-modifying agents among newly diagnosed multiple myeloma patients

    by Jenny S. Guadamuz, Rebecca Rohrer, Ghulam Rehman Mohyuddin, Brian C.-H. Chiu, Pritesh R. Patel, Karen Sweiss, Erlene Seymour, Douglas Sborov, Gregory S. Calip

    Introduction: There are racial/ethnic disparities in multiple myeloma (MM) treatment, including differences in the use of novel agents, stem cell transplantation, and supportive therapies such as bone-modifying agents (BMAs). BMAs reduce the frequency of fractures and skeletal-related pain, and some evidence suggests that more recently approved agents (i.e., denosumab) confer greater progression-free survival benefits than older agents (i.e., bisphosphonates). Here we describe disparities in the initiation of BMA use and uptake of denosumab among newly diagnosed MM patients by race/ethnicity. Methods: We conducted a retrospective cohort study using the nationwide Flatiron Health electronic health record-derived de-identified database. This analysis included adults (≥ 18 years) newly diagnosed with MM between January 2018 and September 2021 who initiated first-line therapy. Patient demographics and clinical characteristics were determined using structured and unstructured data, curated via technology-enabled abstraction. Cumulative incidence functions accounting for competing risks were used to estimate the initiation of BMA use within 90 days before the start of first-line MM therapy and 30 days post. We used multivariable logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for differences in the receipt of denosumab versus bisphosphonates alone (zoledronic acid or pamidronate) among patients who initiated BMA use. Results: Among 4460 newly diagnosed MM patients, 52% were White, 17% were Black, 7% were Latinx, and 2% were Asian. Overall, 2208 (50%) initiated BMA treatment, and utilization differed across racial/ethnic groups with higher rates observed among Asian (55%), White (51%), and Latinx (50%) patients compared to Black patients (44%) (P=0.023). Among patients that initiated BMAs, 53% received denosumab and 47% received bisphosphonates alone. Compared to White patients, Black (OR 1.06, 95% CI 0.83-1.36) and Asian (OR 0.82, 95% CI 0.44-1.53) patients had similar odds of receiving denosumab, whereas Latinx patients had significantly lower odds of receiving denosumab (OR 0.56, 95% CI 0.40-0.79). Conclusion: Among newly diagnosed MM patients, approximately half initiated BMAs. Substantial racial/ethnic disparities exist. For example, Black patients were less likely to receive any BMAs, and, even when treated, Latinx patients were less likely to receive denosumab. Future research should determine whether these treatment disparities impact progression-free and overall survival in real-world MM data. Citation Format: Jenny S. Guadamuz, Rebecca Rohrer, Ghulam Rehman Mohyuddin, Brian C.-H. Chiu, Pritesh R. Patel, Karen Sweiss, Erlene Seymour, Douglas Sborov, Gregory S. Calip. Racial/ethnic disparities in treatment with bone-modifying agents among newly diagnosed multiple myeloma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3669.